Kringle Pharma (TSE:4884) ROCE %: -72.79% (As of Mar. 2026)


TSE:4884 Kringle Pharma Inc TSE:4884
45 GF Score
Price 円318.00
GF Value 円497.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma ROCE %?

Kringle Pharma TSE:4884 +2.91% 45 ROCE % is -72.79% as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 45/100 and a GF Value™ of 円497.82 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kringle Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -72.79%.

Kringle Pharma  (TSE:4884) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kringle Pharma ROCE % Related Terms

Kringle Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma ROCE % Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial -15.23 -15.35 -32.58 -32.47 -39.55

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -43.32 -34.02 -41.46 -72.79
TSE:4884
45GF Score
Kringle Pharma Inc TSE:4884
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma ROCE % Calculation

Kringle Pharma's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=-909.452/( ( (2757.113 - 128.172) + (2079.363 - 109.347) )/ 2 )
=-909.452/( (2628.941+1970.016)/ 2 )
=-909.452/2299.4785
=-39.55 %

Kringle Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-1261.464/( ( (1990.523 - 103.072) + (1988.699 - 410.335) )/ 2 )
=-1261.464/( ( 1887.451 + 1578.364 )/ 2 )
=-1261.464/1732.9075
=-72.79 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -72.79% mean?
Kringle Pharma (TSE:4884) has a ROCE % of -72.79% as of Mar. 2026.
Is Kringle Pharma's ROCE % too high?
Kringle Pharma's current ROCE % is -72.79%. Overall, Kringle Pharma has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's ROCE % compare to VRTX and REGN?
Kringle Pharma's ROCE % of -72.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Kringle Pharma's current ROCE % is -72.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円497.82, compared to a current price of 円318.00 — trading 36.1% below its estimated fair value. The current ROCE % is -72.79%. Kringle Pharma's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current ROCE % is -72.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円318.00 is trading 36.1% below its estimated GF Value™ of 円497.82. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • ROCE %: -72.79%
  • GF Value™: 円497.82 vs. price of 円318.00 (36.1% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
45GF Score

Get the complete analysis for TSE:4884

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円318.00
Price
円497.82
GF Value